Study of BDTX-1535, in Participants With Glioblastoma or Non-Small Cell Lung Cancer
Purpose of Study:
This is a first-in-human, open label, multicenter study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and the preliminary antitumor activity of BDTX-1535 in patients with GBM or NSCLC harboring sensitive EGFR alterations and who have disease progression following standard of care
March 31, 2022 - September 30, 2024
Black Diamond Therapeutics, Inc.
BDTX Clinical Team
ContactPhone: 617- 252-0848
ContactEmail: [email protected]